Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.

ABSTRACT:

Aim

To assess cardiorenal outcomes by baseline urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in the contemporary LEADER cohort.

Materials and methods

LEADER was a multinational, double-blind trial. Patients with type 2 diabetes and high cardiovascular (CV) risk were randomized 1:1 to the glucagon-like peptide-1 analogue liraglutide (≤1.8 mg daily; n = 4668) or placebo (n = 4672) plus standard care and followed for 3.5 to 5 years. Primary composite outcomes were time to first non-fatal myocardial infarction, non-fatal stroke or CV death. Post hoc Cox regression analyses of outcomes by baseline UACR and eGFR subgroups were conducted with adjustment for baseline variables.

Results

In the LEADER population, 1598 (17.5%), 2917 (

SUBMITTER: Mosenzon O 

PROVIDER: S-EPMC7689857 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature